The Biden administration said it expects the new Pfizer and Moderna vaccines targeting the omicron variant XBB.1.5 to be available in mid-September. 

Moderna, Pfizer and Novavax are slated to roll out new vaccines targeting XBB.1.5 within weeks, pending approvals from the FDA.

Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.

The drugmakers designed their updated coronavirus shots to target the omicron subvariant XBB.1.5, which is slowly declining nationwide.

Pfizer, Moderna and Novavax are slated to deliver new single-strain Covid shots targeting the omicron subvariant XBB.1.5 in September.

Pfizer, Moderna and Novavax have not disclosed the exact pricing of their new vaccines, which will target the circulating omicron subvariant XBB.1.5. 

Moderna said the submission is based on the FDA’s recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5.

The FDA’s decision is a win for vaccine makers Pfizer, Moderna and Novavax, which have all been developing versions of their Covid shots to target XBB.1.5.

The FDA advisory panel’s recommendation is a win for Covid vaccine makers Pfizer, Moderna and Novavax, which will race to deliver updated shots for the fall.

Vaccine manufacturers Pfizer, Moderna and Novavax will be expected to update their shots according to the strain the FDA selects for the fall.